A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 301–400 of 999
Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment
Derhovanessian, A., Tazelaar, H. D., Belperio, J. A., & Lynch, J. P. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0038-1660874 · Cited by 57
Health‐related quality of life for patients with vasculitis and their spouses
Carpenter, D. M., Thorpe, C. T., Lewis, M. A., DeVellis, R. F., & Hogan, S. L. (2009) · Arthritis Care & Research · doi:10.1002/art.24235 · Cited by 49
Case 23-2013: A 54-Year-Old Woman with Abdominal Pain, Vomiting, and Confusion
Kalantar-Zadeh, K., Uppot, R. N., & Lewandrowski, K. B. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1208154 · Cited by 49
Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
Salama, A. D. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.10.005 · Cited by 49
Thery-Casari, C., Euvrard, R., Mainbourg, S., Durupt, S., Reynaud, Q., Durieu, I., Bélot, A., Lobbes, H., Cabrera, N., & Lega, J. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102505 · Cited by 49
Pharmacological Therapy for Wegener???s Granulomatosis
White, E. S., & Lynch, J. P. (2006) · Drugs · doi:10.2165/00003495-200666090-00004 · Cited by 49
Berti, A., Boukhlal, S., Groh, M., & Cornec, D. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1697678 · Cited by 54
“Remission-maintenance strategies involving AZA [71], methotrexate [72], or mycophenolate mofetil [73,74] have less closely been investigated in EGPA than in GPA or MPA.”
InfluentialPagnoux, C., Carette, S., KHALIDI, N. A., Walsh, M. W., Hiemstra, T. F., Cuthbertson, D. D., Langford, C. A., Hoffman, G. C., Koening, C. L., Monach, P. A., et al. (2015) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 51
Self-citationReview article: Progress of treatment in ANCA‐associated vasculitis
Jayne, D. R. W. (2009) · Nephrology · doi:10.1111/j.1440-1797.2009.01101.x · Cited by 55
“The efficacy of sequential regimens that substitute azathioprine or methotrexate after 3 to 6 months of cyclophosphamide has been confirmed.(17) This approach permits low levels of cyclophosphamide exposure, usually under 12 g, for pulsed regimens.”
BackgroundInfluentialSelf-citationDay, C. J., Howie, A. J., Nightingale, P., Shabir, S., Adu, D., Savage, C. O. S., & Hewins, P. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.10.047 · Cited by 48
Marco, H., Mirapeix, E., Arcos, E., Comas, J., Ara, J., Gil‐Vernet, S., Puig, J. M., Vinyas, O., Perelló, M., Oppenheimer, F., et al. (2013) · Clinical Transplantation · doi:10.1111/ctr.12084 · Cited by 48
Self-citationAdverse effects of therapy for ANCA-associated vasculitis
Turnbull, J., & Harper, L. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.04.002 · Cited by 48
Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
Mukhtyar, C. B., Hellmich, B., Jayne, D. R. W., Floßmann, O., & Luqmani, R. A. (2006) · PubMed · Cited by 48
Self-citationSolans, R., Rodríguez‐Carballeira, M., Blanco, J. J. R., Fraile, G., Comet, L. S., Martínez-Zapico, A., Frutos, B., Solanich, X., Fonseca-Aizpuru, E. M., Pasquau, F., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23912 · Cited by 48
Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment?
Sneller, M. C. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20717 · Cited by 48
ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
Austin, K., Janagan, S., Wells, M., Crawshaw, H., McAdoo, S. P., & Robson, J. C. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s284768 · Cited by 55
Lionaki, S., Jennette, J. C., & Falk, R. J. (2007) · Seminars in Immunopathology · doi:10.1007/s00281-007-0093-0 · Cited by 48
“Conversion from cyclophosphamide to azathioprine at a dose of 2 mg kg day has been proven a safe and less toxic choice [18, 78].”
BackgroundANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features–outcome
Siomou, E. C., Tramma, D., Bowen, C., & Milford, D. V. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2198-5 · Cited by 47
Management of Alveolar Hemorrhage in Lung Vasculitides
Casian, A., & Jayne, D. R. W. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1279830 · Cited by 48
Self-citationEpidemiology of Glomerular Disease in Southern Arizona
Murugapandian, S., Mansour, I. S. M., Hudeeb, M., Hamed, K., Hammode, E., Bijin, B., Daheshpour, S., Thajudeen, B., & Kadambi, P. V. (2016) · Medicine · doi:10.1097/md.0000000000003633 · Cited by 46
Burns, T. M., Schaublin, G. A., & Dyck, P. J. B. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2006.11.002 · Cited by 47
Benenson, E., Fries, J. W. U., Heilig, B., Pollok, M., & RUBBERT, A. (2004) · Clinical Rheumatology · doi:10.1007/s10067-004-1002-8 · Cited by 46
“Various studies have demonstrated that oral AZA is able tomaintain stable remission in LN [23] andWGwith renal involvement [1] or orbital pseudotumor [24].”
BackgroundS1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
Schirmer, J. H., & Moosig, F. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0393-2 · Cited by 45
“Die Kombination aus hoch dosierten GC mit einer remissionsinduzierendenSubstanz ist inderBehandlung derAAV etabliert undwurde auch in den verfügbaren randomisiert kontrollierten Studien in der Regel in dieser Dosierung verwendet [45, 59, 60, 85, 86, 103, 106, 111, 173, 226].”
Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis
Fortin, P. M., Tejani, A. M., Bassett, K. L., & Musini, V. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007057.pub3 · Cited by 45
Ahmed, A., & Foster, C. S. (2018) · Ophthalmic Research · doi:10.1159/000486791 · Cited by 45
Trejo, M. A. C. W., Floßmann, O., Westman, K. W. A., Höglund, P., Hagen, E. C., Walsh, M. W., Bruijn, J. A., Jayne, D. R. W., Bajema, I. M., & Berden, A. E. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key260 · Cited by 45
Self-citationMechanisms of vascular damage in ANCA vasculitis
Massicotte‐Azarniouch, D., Herrera, C. A., Jennette, J. C., Falk, R. J., & Free, M. E. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00920-0 · Cited by 52
Impact of rituximab trials on the treatment of ANCA-associated vasculitis
Alberici, F., & Jayne, D. R. W. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft318 · Cited by 47
“Bladder, haematological and gonadal toxicity [11, 12] have limited the duration of CYC and inspired lower CYC dosing as used in intravenous (IV) protocols [13].”
BackgroundSelf-citationRomeu, M., Couchoud, C., Delarozière, J.-C., Burtey, S., Chiche, L., Harlé, J., Gondouin, B., Brunet, P., Berland, Y., & Jourde‐Chiche, N. (2014) · QJM · doi:10.1093/qjmed/hcu043 · Cited by 47
“5 NS Median age at the start of dialysis (IQR) 70 (60–78) 71 (62–77) 69 (59–77) NS Renal allograft, n (%) 58 (14) 19 (11) 39 (15) NS Median graft delay, months (IQR) 24 (14–43) 23 (12–45) 26 (16–39) NS First treatment modality NS Hemodialysis in hospital center 380 (90) 144 (87) 236 (91) Hemodialysis, other 18 (4) 8 (…”
血管炎症候群の診療ガイドライン(循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告))
尾崎, 承., 安藤, 太., 居石, 克., 磯部, 光., 太田, 敬., 小林, 茂., 重松, 宏., 種本, 和., 中島, 康., 中林, 公., et al. (2008) · Japanese Circulation Journal-english Edition · Cited by 44
ANCA associated vasculitis (AAV): a review for internists
Yaseen, K., & Mandell, B. F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2102368 · Cited by 45
“The rate of AAV flare after achieving remission varies between 5% of patients on aggressive maintenance therapy [83] and up to 80–90% of patients who are not receiving any maintenance therapy [64,77,82].”
BackgroundResultAn approach to the diagnosis and management of systemic vasculitis
Miller, A., Chan, M., Wiik, A. S., Misbah, S., & Luqmani, R. A. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04078.x · Cited by 43
Management of ANCA-associated vasculitis: Current trends and future prospects
Pusey, C. D., Hamour, S., & Salama (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s6112 · Cited by 50
Self-citationDiagnosis and treatment in inflammatory neuropathies
Lunn, M. P., & Willison, H. J. (2009) · Postgraduate Medical Journal · doi:10.1136/jnnp.2008.158303 · Cited by 43
Watanabe, H., Sada, K., Matsumoto, Y., Harigai, M., Amano, K., Dobashi, H., Fujimoto, S., Usui, J., Yamagata, K., Atsumi, T., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40538 · Cited by 43
“Renal remission was also defined as stable or decreasing creatinine levels and the absence of red cell casts (13,14).”
BackgroundAntineutrophil cytoplasmic antibody-associated vasculitides
Puéchal, X. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.02.001 · Cited by 44
Challenges in the management of microscopic polyangiitis: past, present and future
Jayne, D. R. W. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f370d1 · Cited by 43
Self-citationGenetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitis
Alberici, F., Martorana, D., & Vaglio, A. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu386 · Cited by 48
Clinical features and diagnosis of small-vessel vasculitis
Langford, C. A. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79.s3.01 · Cited by 40
Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes
Shi, L. (2017) · Rheumatology International · doi:10.1007/s00296-017-3818-y · Cited by 42
“In the CYCAZAREM study [19] (Cyclophosphamide versus Azathioprine for Early Remission Phase of Vasculitis), following induction of remission with prednisolone plus oral CYC, 144 newly diagnosed AAV patients were randomized to receive either AZA (2 mg/kg/day) or CYC (1.”
BackgroundMethodInfluentialControversies in small vessel vasculitis – comparing the rheumatology and nephrology views
Falk, R. J., & Hoffman, G. S. (2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328011cb80 · Cited by 42
Diagnostic Approach to ANCA-associated Vasculitides
Gaffo, A. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.05.009 · Cited by 44
Antunes, T., & Barbas, C. S. V. (2005) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132005000700007 · Cited by 41
Pulmonary renal syndrome: a clinical review
Boyle, N., O’Callaghan, M., Ataya, A., Gupta, N., Keane, M. P., Murphy, D. J., & McCarthy, C. (2022) · Breathe · doi:10.1183/20734735.0208-2022 · Cited by 46
Rituximab in Refractory Ophthalmic Wegener's Granulomatosis
Joshi, L., Lightman, S., Salama, A. D., Shirodkar, A., Pusey, C. D., & Taylor, S. R. J. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.06.009 · Cited by 41
Self-citationClinical review: Vasculitis on the intensive care unit -- part 2: treatment and prognosis.
Semple, D. J., Keogh, J., Forni, L., & Venn, R. M. (2004) · Critical Care · doi:10.1186/cc2937 · Cited by 41
“For example, progression to end-stage renal failure eventually occurs in up to 20–25% of patients with WG or MPA in the absence of active inflammation [3,4,40].”
InfluentialLong-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis
Roccatello, D., Sciascia, S., Rossi, D., Alpa, M., Naretto, C., Russo, A., Menegatti, E., & Baldovino, S. (2011) · American Journal of Nephrology · doi:10.1159/000329535 · Cited by 41
“General experience and results of quoted randomized controlled trials [13–15] indicate that 10% of patients with ANCA-associated vasculitis are cyclophosphamide-resistant.”
Ellis, C. L., Manno, R., Havill, J. P., Racusen, L. C., & Geetha, D. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-210 · Cited by 41
“Renal involvement is considered a severe disease manifestation of AAV and progression to end stage renal disease can be prevented by prompt diagnosis and timely initiation of immunosuppressive therapy established by randomized controlled trials [6,7].”
BackgroundMerkel, P. A., Seo, P., Aries, P., Neogi, T., Villa‐Forte, A., Boers, M., Cuthbertson, D. D., Felson, D. T., Hellmich, B., Hoffman, G. S., et al. (2005) · PubMed · Cited by 41
Self-citationde Souza, A. W. S., Calich, A. L., Mariz, H. D. A., Ochtrop, M. L. G., Bacchiega, A. B. S., Ferreira, G. A., Rêgo, J., Perez, M. O., Pereira, R. M. R., Bernardo, W. M., et al. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.06.003 · Cited by 44
Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art
Bonatti, F., Reina, M., Neri, T. M., & Martorana, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00577 · Cited by 47
“Microscopic polyangiitis is associated with proteinase 3 (PR3)ANCA in 26% of cases and with myeloperoxidase (MPO)-ANCA in 58% of cases (5), while GPA is characterized by PR3-ANCA in 66% of patients and MPO-ANCA in 24% of patients (6).”
BackgroundMethodValue of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?
Moosig, F., Holle, J. U., & Gross, W. L. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2826 · Cited by 40
Self-citationMonti, S. M., Craven, A., Klersy, C., Montecucco, C., Caporali, R. F., Watts, R. A., Merkel, P. A., Luqmani, R. A., Collaborators, D., Achilleos, K. M., et al. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa215 · Cited by 40
Updates for the treatment of EGPA
Raffray, L., & Guillevin, L. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104036 · Cited by 44
Zhao, J., Yang, R., Cui, Z., Chen, M., Zhao, M., & Wang, H. (2007) · Nephron Clinical Practice · doi:10.1159/000107803 · Cited by 40
Azar, L., Springer, J. M., Langford, C. A., & Hoffman, G. S. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38744 · Cited by 39
Heijl, C., Westman, K. W. A., Höglund, P., & Mohammad, A. J. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.181438 · Cited by 39
Self-citationLhote, F. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.02.018 · Cited by 43
Pulicken, M., Bash, C. N., Costello, K., Said, A. T., Cuffari, C., Wilterdink, J. L., Rogg, J. M., Mills, P., & Calabresi, P. A. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1141oa · Cited by 39
Moura, M. C., Specks, U., Tehranian, S., Sethi, S. M., Zubidat, D., Nardelli, L., dos Santos, F. G., Sousa, C., León-Román, J. C., Bobart, S. A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06460622 · Cited by 38
“30 kg/m(2) (obese) 33 (34) 23 (46) Laboratory findings Hemoglobin, mean (SD), g/dl 10.”
Buzzard, K. A., Meyer, N. J., Hardy, T. A., Riminton, S., & Reddel, S. (2014) · Muscle & Nerve · doi:10.1002/mus.24536 · Cited by 38
“These protocols have been used successfully in clinical trials of patients with lupus nephritis, granulomatosis with polyangiitis, and microscopic polyangiitis, and have been shown to result in reduced toxicity without compromising efficacy.(6,7) Here we report on the efficacy, durability, and safety of remission-indu…”
BackgroundMethodUpdate on the classification of vasculitis
Waller, R., Ahmed, A., Patel, I., & Luqmani, R. A. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.12.002 · Cited by 38
Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
Sanders, J., Slot, M. C., & Stegeman, C. A. (2003) · New England Journal of Medicine · doi:10.1056/nejm200311203492116 · Cited by 38
Immunotherapeutics for Autoimmune Encephalopathies and Dementias
McKeon, A. B. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0251-8 · Cited by 37
The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China
Li, Z., Ma, T., Chen, M., & Zhao, M. (2015) · Kidney Diseases · doi:10.1159/000441912 · Cited by 39
Interventions for renal vasculitis in adults. A systematic review
Walters, G. D., Willis, N. S., & Craig, J. C. (2010) · BMC Nephrology · doi:10.1186/1471-2369-11-12 · Cited by 37
“The use of AZA to reduce exposure to CPA is assessed by Jayne et al [39].”
MethodTherapeutics of Wegener's granulomatosis
Wung, P. K., & Stone, J. H. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0139 · Cited by 37
Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis
Hirayama, K., Kobayashi, M., Hashimoto, Y., Usui, J., Shimizu, Y., Hirayama, A., Yoh, K., Yamagata, K., Nagase, S., Nagata, M., et al. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.03.030 · Cited by 37
Advances in the Treatment of Small Vessel Vasculitis
Molloy, E. S., & Langford, C. A. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.12.002 · Cited by 37
“MPA differs from WG in several aspects, including a lack of granuloma formation, a predominance of MPO rather than PR3-ANCA antigen specificity, rarity of ENT involvement, and the suggestion from some studies of a lower tendency to relapse after successful remission induction [11].”
BackgroundMethodInfluentialWegener's Granulomatosis: Evolving Concepts in Treatment
Lynch, J. P., White, E. S., Tazelaar, H. D., & Langford, C. A. (2004) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2004-836143 · Cited by 35
“In that study, 155 patients with ANCA-associated vasculitis were treated with daily oral CYC/CS as induction therapy for a minimum of 3 to 6 months.(305) Ninety-five patients (61%) had WG; 60 patients (39%) had MPA.”
BackgroundMethodResultCurrent Attitudes to the Therapy of Vasculitis
Jayne, D. R. W. (2003) · Kidney & Blood Pressure Research · doi:10.1159/000072990 · Cited by 37
Self-citationRituximab Induced Remission in a Patient with Wegener’s Granulomatosis
Kallenbach, M., Duan, H., & Ring, T. (2005) · Nephron Clinical Practice · doi:10.1159/000083426 · Cited by 37
Rituximab in ANCA-Associated Disease
Falk, R. J., & Jennette, J. C. (2010) · New England Journal of Medicine · doi:10.1056/nejme1004992 · Cited by 37
Use of methotrexate in ANCA-associated vasculitides.
Reinhold‐Keller, E., & de Groot, K. (2010) · PubMed · Cited by 36
Lally, L., & Spiera, R. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.01.004 · Cited by 36
Tómasson, G., Davis, J. C., Hoffman, G. S., McCune, W. J., Specks, U., Spiera, R., Clair, E. W. S., Stone, J. H., & Merkel, P. A. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38248 · Cited by 36
B-Cell Depletion in Wegener’s Granulomatosis
Hinze, C. H., & Colbert, R. A. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8057-7 · Cited by 36
Statkute, L., Oyama, Y., Barr, W. G., Sufit, R. L., Ho, S., Verda, L., Loh, Y., Yaung, K., Quigley, K., & Burt, R. K. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070227 · Cited by 36
Novel Therapies for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Lee, R. W., & D’Cruz, D. P. (2008) · Drugs · doi:10.2165/00003495-200868060-00003 · Cited by 39
State of the Art in the Treatment of Systemic Vasculitides
Luqmani, R. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00471 · Cited by 43
“Cyclophosphamide is the gold standard for multi-system small vessel vasculitis (22, 23); for less aggressive forms of disease, there is a potential role for leflunomide (24), methotrexate (25) or in one small series, high dose intravenous azathioprine (13).”
BackgroundInfluentialAnti–B Cell Antibody Therapies for Inflammatory Rheumatic Diseases
Faurschou, M., & Jayne, D. R. W. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-070912-133235 · Cited by 39
Self-citationUpdate on Diffuse Lung Disease in Children
Vece, T. J., & Young, L. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1986 · Cited by 35
“courses as an induction phase of therapy, followed by maintenance with less toxic medications, including methotrexate or azathioprine.(22,23) Although not studied in pediatric patients, alternative long-term therapy protocols for ANCA-associated vasculitis have been assessed in recent studies.”
Methodde Joode, A. A. E., Sanders, J., Puéchal, X., Guillevin, L., Hiemstra, T. F., Floßmann, O., Rasmussen, N., Westman, K. W. A., Jayne, D. R. W., & Stegeman, C. A. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex281 · Cited by 35
Self-citationTan, J., Choi, H. K., Xie, H. W., Sayre, E. C., Esdaile, J. M., & Aviña-Zubieta, J. A. (2018) · Arthritis Care & Research · doi:10.1002/acr.23587 · Cited by 35
“This may be due to changes in our clinical practice, in which azathioprine was increasingly used as maintenance therapy, notably as a result of a number of landmark trials published during the same time period as that for our late cohort (47,48).”
ResultLong term follow-up of Behçet’s syndrome patients treated with cyclophosphamide
Gürcan, M., Esatoğlu, S. N., Hamuryudan, V., Saygın, D., Uğurlu, S., Seyahi, E., Melikoğlu, M., Fresko, İ., Yurdakul, S., Yazıcı, H., et al. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez598 · Cited by 35
Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy
Miszalski−Jamka, T., Szczeklik, W., Sokołowska, B. M., Miszalski‐Jamka, K., Karwat, K., Grządziel, G., Mazur, W. M., Kereiakes, D. J., & Musiał, J. (2011) · European Radiology · doi:10.1007/s00330-011-2203-6 · Cited by 35
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
Merkel, P. A., Herlyn, K., Mahr, A., Neogi, T., Seo, P., Walsh, M. W., Boers, M., & Luqmani, R. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090373 · Cited by 35
Pagnoux, C., & Teixeira, L. (2007) · La Presse Médicale · doi:10.1016/j.lpm.2007.02.015 · Cited by 35
Muso, E., Ito‐Ihara, T., Ono, T., Imai, E., Yamagata, K., Akamatsu, A., & Suzuki, K. T. (2004) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2004.s17 · Cited by 35
“These presentations are fatal when untreated but now around 90% achieve disease control with the combination of corticosteroids and the alkylating agent cyclophosphamide ( 3 ).”
BackgroundPauci-Immune Necrotizing Glomerulonephritis
Rutgers, A., Sanders, J., Stegeman, C. A., & Kallenberg, C. G. M. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.05.002 · Cited by 34
King, C., Druce, K. L., Nightingale, P., Kay, E., Basu, N., Salama, A. D., & Harper, L. (2021) · Rheumatology Advances in Practice · doi:10.1093/rap/rkab018 · Cited by 34
Impaired Health-related Quality of Life in Patients Treated for Wegener’s Granulomatosis
Faurschou, M., Sigaard, L., Bjørner, J. B., & Baslund, B. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100167 · Cited by 38
Cybulsky, A. V., Walsh, M. W., Knoll, G. A., Hladunewich, M., Bargman, J. M., Reich, H. N., Humar, A., Samuel, S. M., Bitzan, M. M., Zappitelli, M., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.001 · Cited by 36
Therapeutic advances in the treatment of vasculitis
Eleftheriou, D., & Brogan, P. A. (2016) · Pediatric Rheumatology · doi:10.1186/s12969-016-0082-8 · Cited by 33
“No differences in remission or relapse rates were observed [20].”
BackgroundMethodInfluentialRahmattulla, C., van Wijngaarden, R. A. F. D. L., Berden, A. E., Hauer, H. A., Floßmann, O., Jayne, D. R. W., Gaskin, G., Rasmussen, N., Noël, L., Ferrario, F., et al. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu357 · Cited by 33
Self-citationStrand, V., Jayne, D. R. W., Horomanski, A. L., Yue, H., Bekker, P. J., Merkel, P. A., Peh, C. A., Chakera, A., Cooper, B. A., Kurtkoti, J., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00092-9 · Cited by 37
Self-citationPersistent Hematuria After Induction of Remission in Wegener Granulomatosis
Magrey, M., Villa‐Forte, A., Koening, C. L., Myles, J. L., & Hoffman, G. S. (2009) · Medicine · doi:10.1097/md.0b013e3181c101cc · Cited by 32
Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis
Ranganathan, D., Lazarus, B., John, G. T., & O’Callaghan, C. J. (2016) · Indian Journal of Nephrology · doi:10.4103/0971-4065.171225 · Cited by 32
“In the 1 st year, almost 50% CYCAZAREM [54] 115 patients with newly diagnosed AAV and renal involvement AZA vs. oral CYC, both in combination with prednisolone, after achieving remission with oral CYC and steroids Relapse at 18 months AZA and CYC associated with similar rates of relapse.”
BackgroundInfluentialNonsystemic Vasculitic Neuropathy: Update on Diagnosis, Classification, Pathogenesis, and Treatment
Collins, M. P., & Periquet‐Collins, I. (2009) · Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences · doi:10.1159/000212368 · Cited by 35
Geetha, D., Kallenberg, C. G. M., Stone, J. H., Salama, A. D., Appel, G. B., Duna, G. F., Brunetta, P. G., & Jayne, D. R. W. (2014) · Journal of Nephrology · doi:10.1007/s40620-014-0135-3 · Cited by 32
“For remission-maintenance, the CYCAZAREM trial showed that cyclophosphamide could be replaced with azathioprine after remission without increasing the rate of relapse [17].”
BackgroundSelf-citation
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.